International Liver Cancer Association (ILCA) Avenue de Tervueren, 300 B-1150 Brussels Belgium info@ilca-online.org +32 (0)2 789 2345 +32 (0)2 743 1550 |
Sponsors and ExhibitorsPlatinum Sponsor  Bayer Schering Pharma is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer Schering Pharma's oncology business unit includes a global group of dedicated individuals working to develop solutions that improve the lives of cancer patients. Through compassion and collaboration, Bayer continues to discover new treatments to help improve the health of cancer patients worldwide. Bayer Schering Pharma's research efforts have resulted in a balanced, diverse portfolio of potential cancer therapies. The Company is proud to contribute to liver cancer research, development and education through support of the International Liver Cancer Association. Gold Sponsor  Novartis Oncology delivers a broad range of innovative therapies aimed at improving and extending the lives of patients. These include Glivec® (imatinib), Tasigna® (nilotinib), Exjade® (deferasirox), Zometa® (zoledronic acid), Sandostatin® LAR® (octreotide/IM injection) and Femara® (letrozole). Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies. Silver Sponsors   Terumo is a Japanese company which provides a wide range of quality products. Innovating in the field of Interventional Oncology, Biocompatibles has developed the unique concept of Drug Chargeable Beads, the only drug delivery embolization system designed, clinically validated and CE approved for TACE of hypervascularized tumors presently proposed on the market. DC Bead™ is exclusively distributed in Europe by Terumo.  Bracco Imaging S.p.A., is one of the World’s leading companies in the diagnostic imaging business. Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions in over 80 markets worldwide. Bracco Imaging’s products include: SonoVue, intravenous Ultrasound contrast agent for cardiac, neurological and radiological applications, available in Europe, India, South Korea and China. Sponsors  Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing and providing innovative medicines that help patients prevail against serious disease. Our medicines have helped countless patients in the fight against serious diseases such as cancer, HIV/AIDS and psychiatric disorders. In addition, we have stood beside those who are battling rheumatoid arthritis and chronic hepatitis B, heart disease and diabetes. And our philanthropic programs have given new hope to some of the most vulnerable people in the world. What sets Bristol-Myers Squibb apart? It’s our focus on finding innovative medicines to combat serious diseases, and getting them to patients faster and more efficiently.  Delcath Systems is a medical technology company specializing in regional cancer treatment. The Delcath PHP System™ targets high doses of drug to the site of disease while minimizing the systemic exposure, and thereby reducing the toxic side-effects of chemotherapy.  As a world-leading supplier of radiation technologies, MDS Nordion will be promoting their liver cancer treatment TheraSphere: an yttrium-90 therapy delivering uniform, targeted internal radiation and is a safe treatment option for liver cancer. TheraSphere is available in patient specific dosing and is the only treatment options for HCC patients with PVT. It offers downstaging to resection ability and shows minimal side effects when compared with systemic treatments.  Sirtex Medical Europe GmbH is a wholly owned subsidiary of Sirtex Medical Pty Ltd, a publicly listed company on the Australian Exchange engaged in the field of oncology and interventional oncology. Our innovative technology, SIR-Spheres® microspheres, was approved for use in the treatment of unresectable liver cancer within the European Union under CE Mark in October 2002. SIR-Spheres microspheres is presently employed in the treatment of a variety of unresectable metastatic liver tumours as well as in hepatocellular carcinoma at 52 institutions within the European Union including Austria, Belgium, Germany, Italy, Spain, Sweden and United Kingdom.  ILCA 2009 is supported by an educational grant from ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company  Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. Travel Grants Sponsor  |
ConferenceMembershipILCA – an International and Multi-disciplinary
Association for Liver Cancer Experts
Find out more about ILCA Member Benefits and how to become a member. AssociationMission
The International Liver Cancer Association (ILCA) aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer. |
